A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision to stop compound development. The decision was not based on any safety or efficacy concerns. It reflected the company strategy for portfolio progression.

Conditions

HIV Infections

Interventions

DRUG: GSK3640254
DRUG: Dolutegravir
DRUG: Lamivudine capsules
DRUG: Lamivudine tablets

Sponsor

ViiV Healthcare

Collaborators

[object Object]